$ONDS DEEP DIVE, THE NEXT POTENTIAL MULTIBAGGER 🚀🚀

I first initiated a siezable position in $ONDS early this year when it was hovering around $1.80 and $2.

As some of you folks have been seeing I have been buying $ONDS very heavily during this dip and wanted to share my thesis as to why I invested in this company.

My lowest buy: $2.01
Average cost: $4.60
Portfolio percentage: 6.4%

What does $ONDS do?
ONDS is a leading provider of autonomous drone and private wireless solutions through its business units Ondas Autonomous Systems (OAS) and Ondas Networks.

In this thread ill break down their core offerings, use cases, potential TAM, risks and valuation going ahead 🧵👇 1. Core offering: Ondas Networks (∼5-10% of near-term rev)

This is the "critical infrastructure backbone" division.

►Builds dedicated, private LTE/5G-grade wireless networks for industries that cannot afford downtime or rely on commercial carriers (railroads, utilities, oil & gas, mining, defense).
►This is the original business and now carries a multi-decade structural tailwind after dot16 was officially adopted as the North American rail industry standard for the 160 MHz next-gen upgrade.
►This part makes steady money eventually, but it’s been slow as hell because big industries move like dinosaurs.

The win is it’s basically a toll road that will print money for decades once it really ramps.

I’ve often shared my journey with $SOFI, $HIMS, $NBIS, and $ZETA which is the backbone of my portfolio, representing almost 80%. These are my steady, conviction bets.

But I also keep a 23% slice for “swing for the fences” ideas, companies with breakthrough potential, massive upside, but equally high volatility.

In this short thread, I’ll share what’s inside that basket, why I picked them, how they’ve performed so far, and what I see for the future.🧵

1. OSCR – Oscar Health
💼 5% of portfolio | +5.4% All time Returns

Oscar is a digital-first health insurer with 2M+ members across 18 states. Q2 revenue was $2.86B (+29% YoY), though it reported a $228M loss.

Why I invested: I see Oscar as a tech disruptor in a trillion $ industry.

Future: If ACA headwinds like regulatory pressures and risk adjustment drag ease, Oscar could scale profitably. Management guides for 2026 profitability. If margins normalize, Oscar could evolve from niche ACA player to a full-stack digital insurer with national reach. 2. $IREN – IREN Ltd
💼 2.8% of portfolio | +177%

IREN started as a renewable-powered Bitcoin miner but is now also building AI cloud infra with 10.9k Nvidia GPUs. Q4 revenue was $187M (+228% YoY), with margins >50%.

Why I invested: A rare “dual-engine” play on both BTC cycles and AI demand.

Future: If AI workloads keep scaling and Bitcoin adoption continues, IREN could position itself as one of the most efficient, renewable-powered data infra providers in the world. Removing crypto regulatory uncertainty would further de-risk their growth path.

🚀 My Top 10 Positions for 2025 – Deep Dive 🚀

As promised, I’m revealing my top 10 portfolio holdings! 🤑

I’ll break down my percentage allocation, cost averages, when I bought them, and the 2025 catalysts that have me hyped for what’s ahead. 🚀

Stay tuned—this is going to be good!

#1 Position: $HIMS

💰 Portfolio Allocation: 44.8%
📉 Cost Basis: $14
👀 First Bought: Late 2024

I started tracking $HIMS when it was still a small cap and was blown away by its YoY growth, surging customer base, and expanding product lineup. I built my position early and averaged up from there.

Now, 2025 is shaping up to be a breakout year for Hims & Hers. Here’s why I’m bullish:

🔥 Major Catalysts for 2025:

🏈 Super Bowl Ad Debut – $HIMS is making a bold statement with its first-ever Super Bowl commercial, highlighting its weight-loss treatments (GLP-1s) and calling out high healthcare costs. The ad, featuring Donald Glover’s This Is America, reinforces their commitment to affordable & accessible care.
💊 Generic Weight-Loss Medications – $HIMS is set to launch a generic version of liraglutide (GLP-1) by year-end, making effective weight-loss treatments more affordable.
🧬 Hyper-Personalized Wellness – They’re leveraging AI, telehealth, and advanced science to create customized health plans instead of one-size-fits-all treatments.
⚡ New Product Verticals – Expansion into menopause care & testosterone replacement therapy (TRT), addressing hormonal health for both men & women.

$HIMS continues to disrupt healthcare and could see massive upside. 🔥📈 💸 #2 Position: $SOFI

💰 Portfolio Allocation: 36.6%
📉 Cost Basis: $7.19
📅 First Bought: Early 2023

$SOFI was my first-ever investment, and it’s been an incredible ride since then. What drew me in?

1. The fearless leadership of Anthony Noto 💪
2. The resilient SOFI community 🚀 Thanks to @DataDInvesting , @Tim_Sweeney_TAR
3. A mission to be the 1-stop shop for finance in the US 🏦

Fast-forward to 2025, and $SOFI is gearing up for a transformative year. Here’s what I’m watching:

🔥 Major Catalysts for 2025:

🤝 Strategic Partnerships – $SOFI recently inked a $5 billion loan platform deal, signaling massive expansion. And they’ve hinted at more partnerships in the pipeline. Expect big announcements with other financial institutions this year.
🐎 Dark Horse Potential – While the market reacted negatively to their conservative 2025 guidance, don’t count them out:
a. A Crypto platform launch (potentially by Q1/Q2) could be a game-changer.
b. Another Tech Platform deal (like last year’s LPB) could catch the market off guard.

Knowing Noto, he’s likely holding some cards close to his chest for 2025. 👀
$SOFI remains a high-conviction play for me.